http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 19 Feb 2026 16:13:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CURIS+INC+++++++++++++++++For%3A+Mar+17/26029963.html si-local-file:///var/storage/secattach/20260219/26029963.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CURIS+INC+++++++++++++++++For%3A+Mar+17/26029963.html Thu, 19 Feb 2026 16:13:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CURIS+INC+++++++++++++++++For%3A+Mar+17/26029963.html si-local-file:///var/storage/secattach/20260219/26029963.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CURIS+INC+++++++++++++++++For%3A+Mar+17/26029963.html Thu, 19 Feb 2026 16:13:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CURIS+INC++++++++++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26016346.html si-local-file:///var/storage/secattach/20260217/26016346.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CURIS+INC++++++++++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26016346.html Tue, 17 Feb 2026 21:52:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CURIS+INC++++++++++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26016346.html si-local-file:///var/storage/secattach/20260217/26016346.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CURIS+INC++++++++++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26016346.html Tue, 17 Feb 2026 21:52:00 -0500 CRIS O.00176055 http://www.streetinsider.com/Equity+Offerings/Curis+%28CRIS%29+files+for+107.71M+share+offering+by+selling+stockholders/26000688.html <p>Curis (NASDAQ: CRIS) has filed for up to 107,706,700 share offering by selling stockholders.</p> http://www.streetinsider.com/Equity+Offerings/Curis+%28CRIS%29+files+for+107.71M+share+offering+by+selling+stockholders/26000688.html Fri, 13 Feb 2026 16:24:19 -0500 CRIS http://www.streetinsider.com/Corporate+News/Curis+%28CRIS%29+files+for+107.71M+share+offering+by+selling+stockholders/26000688.html <p>Curis (NASDAQ: CRIS) has filed for up to 107,706,700 share offering by selling stockholders.</p> http://www.streetinsider.com/Corporate+News/Curis+%28CRIS%29+files+for+107.71M+share+offering+by+selling+stockholders/26000688.html Fri, 13 Feb 2026 16:24:19 -0500 CRIS http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++CURIS+INC++++++++++++++++++++++++++++/26000642.html si-local-file:///var/storage/secattach/20260213/26000642.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++CURIS+INC++++++++++++++++++++++++++++/26000642.html Fri, 13 Feb 2026 16:22:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++CURIS+INC++++++++++++++++++++++++++++/26000642.html si-local-file:///var/storage/secattach/20260213/26000642.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++CURIS+INC++++++++++++++++++++++++++++/26000642.html Fri, 13 Feb 2026 16:22:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++CURIS+INC+++++++++++++++++For%3A+Mar+17/25968982.html si-local-file:///var/storage/secattach/20260209/25968982.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++CURIS+INC+++++++++++++++++For%3A+Mar+17/25968982.html Mon, 09 Feb 2026 16:55:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++CURIS+INC+++++++++++++++++For%3A+Mar+17/25968982.html si-local-file:///var/storage/secattach/20260209/25968982.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++CURIS+INC+++++++++++++++++For%3A+Mar+17/25968982.html Mon, 09 Feb 2026 16:55:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CURIS+INC+++++++++++++++++For%3A+Feb+03/25968973.html si-local-file:///var/storage/secattach/20260209/25968973.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CURIS+INC+++++++++++++++++For%3A+Feb+03/25968973.html Mon, 09 Feb 2026 16:54:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CURIS+INC+++++++++++++++++For%3A+Feb+03/25968973.html si-local-file:///var/storage/secattach/20260209/25968973.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CURIS+INC+++++++++++++++++For%3A+Feb+03/25968973.html Mon, 09 Feb 2026 16:54:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CURIS+INC++++++++++++++++++++++++++++++Filed+by%3A+M28+Capital+Management+LP/25887268.html si-local-file:///var/storage/secattach/20260123/25887268.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CURIS+INC++++++++++++++++++++++++++++++Filed+by%3A+M28+Capital+Management+LP/25887268.html Fri, 23 Jan 2026 16:15:00 -0500 CRIS O.00176055 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CURIS+INC++++++++++++++++++++++++++++++Filed+by%3A+M28+Capital+Management+LP/25887268.html si-local-file:///var/storage/secattach/20260123/25887268.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CURIS+INC++++++++++++++++++++++++++++++Filed+by%3A+M28+Capital+Management+LP/25887268.html Fri, 23 Jan 2026 16:15:00 -0500 CRIS O.00176055 http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html <p>Curis Inc. (NASDAQ: CRIS) announced the closing of a private placement financing that raised up to $80.8 million in gross proceeds, with initial proceeds of approximately $20.2 million before fees and expenses.</p> <p>The financing was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners LLC and The Red Hook Fund LP. Other new and existing institutional investors participated, along with members of the company's management team and board of directors.</p> <p>Laidlaw & Company (UK) Ltd. served as sole placement agent for the transaction.</p> <p>Curis is a biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor. The drug is currently being evaluated in http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html Fri, 09 Jan 2026 08:00:31 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html <p>Curis Inc. (NASDAQ: CRIS) announced the closing of a private placement financing that raised up to $80.8 million in gross proceeds, with initial proceeds of approximately $20.2 million before fees and expenses.</p> <p>The financing was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners LLC and The Red Hook Fund LP. Other new and existing institutional investors participated, along with members of the company's management team and board of directors.</p> <p>Laidlaw & Company (UK) Ltd. served as sole placement agent for the transaction.</p> <p>Curis is a biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor. The drug is currently being evaluated in http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html Fri, 09 Jan 2026 08:00:31 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html <p>Curis Inc. (NASDAQ: CRIS) announced the closing of a private placement financing that raised up to $80.8 million in gross proceeds, with initial proceeds of approximately $20.2 million before fees and expenses.</p> <p>The financing was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners LLC and The Red Hook Fund LP. Other new and existing institutional investors participated, along with members of the company's management team and board of directors.</p> <p>Laidlaw & Company (UK) Ltd. served as sole placement agent for the transaction.</p> <p>Curis is a biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor. The drug is currently being evaluated in http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html Fri, 09 Jan 2026 08:00:31 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html <p>Curis Inc. (NASDAQ: CRIS) announced the closing of a private placement financing that raised up to $80.8 million in gross proceeds, with initial proceeds of approximately $20.2 million before fees and expenses.</p> <p>The financing was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners LLC and The Red Hook Fund LP. Other new and existing institutional investors participated, along with members of the company's management team and board of directors.</p> <p>Laidlaw & Company (UK) Ltd. served as sole placement agent for the transaction.</p> <p>Curis is a biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor. The drug is currently being evaluated in http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html Fri, 09 Jan 2026 08:00:31 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html <p>Curis Inc. (NASDAQ: CRIS) announced the closing of a private placement financing that raised up to $80.8 million in gross proceeds, with initial proceeds of approximately $20.2 million before fees and expenses.</p> <p>The financing was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners LLC and The Red Hook Fund LP. Other new and existing institutional investors participated, along with members of the company's management team and board of directors.</p> <p>Laidlaw & Company (UK) Ltd. served as sole placement agent for the transaction.</p> <p>Curis is a biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor. The drug is currently being evaluated in http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html Fri, 09 Jan 2026 08:00:31 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html <p>Curis Inc. (NASDAQ: CRIS) announced the closing of a private placement financing that raised up to $80.8 million in gross proceeds, with initial proceeds of approximately $20.2 million before fees and expenses.</p> <p>The financing was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners LLC and The Red Hook Fund LP. Other new and existing institutional investors participated, along with members of the company's management team and board of directors.</p> <p>Laidlaw & Company (UK) Ltd. served as sole placement agent for the transaction.</p> <p>Curis is a biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor. The drug is currently being evaluated in http://www.streetinsider.com/Equity+Offerings/Curis+closes+%2480.8+million+private+placement+led+by+Nantahala+Capital/25829336.html Fri, 09 Jan 2026 08:00:31 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html <div class="xn-content"> <p class="prntac"><i>Led by <span>Nantahala Capital</span>, <span>Stonepine Capital Management</span>, <span>Pointillist Partners, LLC</span>, and <span>The Red Hook Fund, LP</span></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 9, 2026</chron></span> /PRNewswire/ --<b> <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS)</b>, a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to <money>$80.8 million</money> to the Company, including initial gross proceeds to the Company of approximately <money>$20.2 million</money>, in each case before placement agent fees and offering expenses.</p> http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html Fri, 09 Jan 2026 08:00:00 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html <div class="xn-content"> <p class="prntac"><i>Led by <span>Nantahala Capital</span>, <span>Stonepine Capital Management</span>, <span>Pointillist Partners, LLC</span>, and <span>The Red Hook Fund, LP</span></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 9, 2026</chron></span> /PRNewswire/ --<b> <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS)</b>, a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to <money>$80.8 million</money> to the Company, including initial gross proceeds to the Company of approximately <money>$20.2 million</money>, in each case before placement agent fees and offering expenses.</p> http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html Fri, 09 Jan 2026 08:00:00 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html <div class="xn-content"> <p class="prntac"><i>Led by <span>Nantahala Capital</span>, <span>Stonepine Capital Management</span>, <span>Pointillist Partners, LLC</span>, and <span>The Red Hook Fund, LP</span></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 9, 2026</chron></span> /PRNewswire/ --<b> <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS)</b>, a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to <money>$80.8 million</money> to the Company, including initial gross proceeds to the Company of approximately <money>$20.2 million</money>, in each case before placement agent fees and offering expenses.</p> http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html Fri, 09 Jan 2026 08:00:00 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html <div class="xn-content"> <p class="prntac"><i>Led by <span>Nantahala Capital</span>, <span>Stonepine Capital Management</span>, <span>Pointillist Partners, LLC</span>, and <span>The Red Hook Fund, LP</span></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 9, 2026</chron></span> /PRNewswire/ --<b> <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS)</b>, a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to <money>$80.8 million</money> to the Company, including initial gross proceeds to the Company of approximately <money>$20.2 million</money>, in each case before placement agent fees and offering expenses.</p> http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html Fri, 09 Jan 2026 08:00:00 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344 http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html <div class="xn-content"> <p class="prntac"><i>Led by <span>Nantahala Capital</span>, <span>Stonepine Capital Management</span>, <span>Pointillist Partners, LLC</span>, and <span>The Red Hook Fund, LP</span></i></p><p><span class="legendSpanClass"><location value="LU/us.ma.lexton" idsrc="xmltag.org" >LEXINGTON, Mass.</location></span>, <span class="legendSpanClass"><chron>Jan. 9, 2026</chron></span> /PRNewswire/ --<b> <span value="NASDAQ-NMS:CRIS" idsrc="xmltag.org" >Curis, Inc.</span> (NASDAQ: CRIS)</b>, a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to <money>$80.8 million</money> to the Company, including initial gross proceeds to the Company of approximately <money>$20.2 million</money>, in each case before placement agent fees and offering expenses.</p> http://www.streetinsider.com/Press+Releases/Curis+Announces+Closing+of+Private+Placement+Totaling+up+to+%2480.8+Million+in+Gross+Proceeds/25829321.html Fri, 09 Jan 2026 08:00:00 -0500 A.06822034 A.60012004 CRIS O.00176055 O.01304637 O.20026344